Log in to search using one of your social media accounts:

 

HAART Mostly Cardioprotective in Kids with HIV (CME/CE)
(MedPage Today) -- But left ventricular contractility declined with increasing follow-up (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - October 23, 2017 Category: Infectious Diseases Source Type: news

Does HAART Contribute to Syphilis Incidence? Does HAART Contribute to Syphilis Incidence?
A new review examines the possible role HAART may have in the increase of syphilis cases due to susceptibility to infection with T. pallidum.Sexually Transmitted Infections (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 16, 2017 Category: Consumer Health News Tags: Infectious Diseases Journal Article Source Type: news

Which Cancers Secondary to Kaposi Sarcoma Are Emerging in the HAART Era? Which Cancers Secondary to Kaposi Sarcoma Are Emerging in the HAART Era?
Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 1, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

BioStable Science & Engineering wins FDA nod for Haart 200 aortic annuloplasty device
Cardiovascular device developer BioStable Science & Engineering said today it won FDA clearance for its Haart 200 aortic annuloplasty device, touting it as the 1st and only such device designed specifically for bicuspid aortic valve repairs. The Austin, Texas-based company’s Haart 200 aortic annuloplasty device is intended for valve repairs in patients with aortic valve insufficiency due to the congenital bicuspid aortic valve malformation in which the aortic valve forms with only 2 functional valve leaflets instead of 3. Bicuspid aortic valve malformations affect up to 2% of the population and carry a signi...
Source: Mass Device - August 15, 2017 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Food & Drug Administration (FDA) Regulatory/Compliance Replacement Heart Valves BioStable Science & Engineering Source Type: news

MassDevice.com +5 | The top 5 medtech stories for June 14, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. BioStable Science & Engineering begins limited release of Haart 300 annuloplasty device Cardiovascular device developer BioStable Science & Engineering said today it began a limited launch ofits HAART 300 aortic annulop...
Source: Mass Device - June 14, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

BioStable Science & Engineering begins limited release of Haart 300 annuloplasty device
Cardiovascular device developer BioStable Science & Engineering said today it began a limited launch of its HAART 300 aortic annuloplasty device, with the 1st commercial procedure being performed at the West Virginia University Heart and Vascular Institute. The 1st procedure was performed by Dr. Lawrence Wei, Dr. Vinay Badhwar and Dr. J. Rankin, according to the Austin, Texas-based company. “The novel sizing method and simple, quick implantation technique for the HAART 300 aortic annuloplasty device help to standardize the overall repair procedure. Internal annuloplasty has significant advantages over e...
Source: Mass Device - June 14, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Vascular BioStable Science & Engineering Source Type: news

BioStable Science & Eng wins FDA nod for Haart 300 aortic annuloplasty device
Cardiovascular device developer BioStable Science & Engineering said yesterday it won FDA 510(k) clearance for its Haart 300 aortic annuloplasty device. The Austin, Texas-based company touted the Haart 300 as the 1st commercially available internal annuloplasty device designed for aortic valve repair, expected to be available to select US heart centers this summer. “We are very grateful for the cooperation between the BioStable management team and FDA that allowed the company to obtain this market clearance earlier than anticipated, and we look forward to the Haart 300 Aortic Annuloplasty Devi...
Source: Mass Device - March 23, 2017 Category: Medical Equipment Authors: Fink Densford Tags: 510(k) Cardiac Implants Cardiovascular Food & Drug Administration (FDA) Regulatory/Compliance Replacement Heart Valves BioStable Science & Engineering Source Type: news

BioStable Science and Engineering Announces FDA Clearance of the HAART(TM) 300 Aortic Annuloplasty Device
AUSTIN, Texas--(Healthcare Sales & Marketing Network)--BioStable Science & Engineering, Inc. announced today it has received FDA market clearance for the HAART 300 Aortic Annuloplasty Device, the first commercially available internal annuloplasty device de... Devices, Cardiology, FDA BioStable Science & Engineering, HAART 300, Aortic Annuloplasty, aortic valve (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 22, 2017 Category: Pharmaceuticals Source Type: news

HIV treatment makes patients MORE susceptible to syphilis
HAART - a drug treatment used for HIV infection - might be the reason behind rising rates of syphilis, a new study warns. Rates are 107 times higher in gay/bisexual men. (Source: the Mail online | Health)
Source: the Mail online | Health - January 17, 2017 Category: Consumer Health News Source Type: news

AIDS and Cancer Specimen Resource Young Investigator Pilot Award (2017)
The 2017 AIDS and Cancer Specimen Resource (ACSR) Pilot Study Award is targeted toward junior investigators and faculty with innovative ideas for translational, clinical, or behavioral-epidemiological HIV-related research that utilizes ACSR's annotated biospecimens collected from HIV/AIDS patients and controls from both pre and post-HAART periods. (Source: PHPartners.org)
Source: PHPartners.org - January 5, 2017 Category: Global & Universal Source Type: news

HIV, Highly Active Antiretroviral Therapy and the Heart HIV, Highly Active Antiretroviral Therapy and the Heart
What do we know about the cardiometabolic effects of HAART and the risk of cardiovascular disease among HIV-1 infected patients?HIV Medicine (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - October 6, 2016 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

Active surveillance cost effective for first-line HAART in Namibia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 30, 2016 Category: Drugs & Pharmacology Source Type: news

My Apology and a Call to Action on MDR-TB
After a career as a physician in public health I find myself impelled to offer a public apology to quite a few patients, only a fraction of whom I have treated. I have been offering up my apologies to individual patients for a few years, but somehow it doesn't seem to be enough. The situation starts with my description of a particular diagnosis and treatment plan, "Your TB is unfortunately due to a TB germ resistant to the two most powerful drugs for treating TB (INH and rifampin). We call it multi-drug resistant, or MDR-TB. I am confident, with the help of the nurses and other TB clinic staff, that we can cure your T...
Source: Healthy Living - The Huffington Post - March 23, 2016 Category: Consumer Health News Source Type: news

The role of organic transporters in pharmacokinetics and nephrotoxicity of newer antiviral therapies
(Bentham Science Publishers) Highly active antiretroviral therapy and direct acting antiviral agents are key elementsin the effective pharmacotherapy of human immunodeficiency virus and Hepatitis C virus respectively. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 14, 2016 Category: Biology Source Type: news

BioStable Science & Engineering wins CE Mark for annuloplasty device
Cardiovascular device company BioStable Science & Engineering said today it won CE Mark approval in the European Union for its HAART 300 aortic annuloplasty device designed for aortic valve repair. The Austin, Texas-based company said its HAART 300 is an internal aortic annuloplasty ring designed to replicate the anatomy of the aortic valve and resize, reshape and stabilize the aortic annulus to restoe valve competence and prevent recurrent aortic regurgitation. “In patients with mitral and tricuspid valve disease, valve repair has become the standard of care due to superior outcomes compared to biological or mec...
Source: Mass Device - March 8, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Regulatory/Clearance BioStable Science & Engineering Source Type: news

HAART Helps HIV Patients in ICU (CME/CE)
(MedPage Today) -- Treatment useful even when the cause of admission is not HIV-related (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - October 29, 2015 Category: Infectious Diseases Source Type: news

Effective HAART Reduces HBV Risk in Men With HIVEffective HAART Reduces HBV Risk in Men With HIV
Treatment that brought HIV viral loads to undetectable levels also prevented additional susceptibility to HBV, but HBV vaccination is still needed. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 13, 2015 Category: Consumer Health News Tags: HIV/AIDS News Source Type: news

Retention in HAART as a Recurrent Event ProcessRetention in HAART as a Recurrent Event Process
Monitoring HAART retention, dropout, and reentry should be prioritized for HIV surveillance. AIDS (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 6, 2015 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news

Adherence and HIV RNA Suppression in the Era of HAARTAdherence and HIV RNA Suppression in the Era of HAART
This study examines trends in adherence to HAART regimens and how they relate to HIV RNA suppression. JAIDS: Journal of Acquired Immune Deficiency Syndromes (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 11, 2015 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news

Waking up HIV
Highly active anti-retroviral therapy has helped millions survive the human immunodeficiency virus. Unfortunately, HIV has a built-in survival mechanism, creating reservoirs of latent, inactive virus that are invisible to both HAART and the immune system. But now, researchers have identified a compound that activates latent HIV, offering the tantalizing possibility that the virus can be flushed out of the silent reservoirs and fully cured. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 30, 2015 Category: Science Source Type: news

HBV-Active HAART Regimens in an HIV-HBV Multinational CohortHBV-Active HAART Regimens in an HIV-HBV Multinational Cohort
Which method of HAART is preferred to treat HIV-HBV co-infected patients? AIDS (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 21, 2015 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news

Social Factors Tied To Risk for Detectable HIV in PregnancySocial Factors Tied To Risk for Detectable HIV in Pregnancy
Even with HAART, socially disadvantaged women are at higher risk for detectable HIV at delivery during a first pregnancy, a new study suggests. Medscape Medical News (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - January 20, 2015 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Immune Reconstitution Syndrome in HIV InfectionImmune Reconstitution Syndrome in HIV Infection
This HIV+ patient undergoing HAART presented to the emergency room with weakness, headache, neck stiffness and fever. What was the diagnosis? Applied Radiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 19, 2015 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news

Annals of Internal Medicine tip sheet for Jan. 20, 2015
(American College of Physicians) Below are summaries of articles being featured in the next issue of Annals of Internal Medicine, including 'Too much sitting linked to serious health risks and death, regardless of exercise habits,' 'Despite HAART, socially disadvantaged pregnant women with HIV at greater risk for having detectable virus at delivery' and 'Small study makes important discovery about idiopathic pulmonary arterial hypertension.' (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - January 19, 2015 Category: Global & Universal Source Type: news

Late Initiation of HAART in HIV+ Young AdultsLate Initiation of HAART in HIV+ Young Adults
Which patient factors make a young adult with HIV more likely to initiate late HAART? Journal of the International Association of Providers of AIDS Care (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 21, 2014 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news

Highlights on HIV Eradication in 2013Highlights on HIV Eradication in 2013
Almost 20 years after the introduction of HAART, we are still struggling to find a way to eradicate HIV. Is a cure for HIV infection achievable? AIDS (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - January 22, 2014 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

The Year in HIV/AIDS: Ten News Stories That Defined 2013
There have been years that one could rightly proclaim as being pivotal in the global fight against HIV/AIDS -- among them, the ACTG 076 study in 1994, which demonstrated the efficacy of antiretrovirals in preventing mother-to-child transmission; the introduction of protease inhibitors and HAART in 1996; and the founding of The Global Fund and PEPFAR in 2002....Read Full Post (Source: About AIDS / HIV)
Source: About AIDS / HIV - December 13, 2013 Category: Consumer Health News Source Type: news

HIV cure may lie in radioimmunotherapy
A new study suggests targeting HIV with radioimmunotherapy could eradicate HIV from infected cells. If given in conjunction with highly active antiretroviral therapy, it may form the basis of a cure.Although highly active antiretroviral therapy (HAART) kills human immunodeficiency virus (HIV) in the bloodstream, it does not completely eliminate it from the body because the virus can linger in infected cells and replicate. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 5, 2013 Category: Consumer Health News Tags: HIV / AIDS Source Type: news

Radioimmunotherapy shows promise for possible HIV cure
Researchers have used radioimmunotherapy (RIT) to destroy remaining human immunodeficiency virus (HIV)-infected cells in the blood samples of patients treated with antiretroviral therapy, offering the promise of a strategy for curing HIV infection. Results of the study were presented at the annual meeting of the Radiological Society of North America (RSNA).Highly active antiretroviral therapy (HAART) has transformed the outlook for patients infected with HIV by suppressing the replication of the virus in the body. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 4, 2013 Category: Consumer Health News Tags: HIV / AIDS Source Type: news

Alternative to Standard HAART Regimen May Be Better Alternative to Standard HAART Regimen May Be Better
Dolutegravir plus abacavir-lamivudine was safer and more effective against HIV-1 infection than an efavirenz, tenofovir DF, and emtricitabine combination, in a randomized, controlled trial. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 6, 2013 Category: Consumer Health News Tags: HIV/AIDS News Source Type: news

Effect of HCV in HIV-Infected Patients Initiating HAARTEffect of HCV in HIV-Infected Patients Initiating HAART
How does HCV affect the immunological and virological responses in HIV-infected patients starting HAART? Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 15, 2013 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Viral Load Monitoring and Outcomes in HAART PatientsViral Load Monitoring and Outcomes in HAART Patients
Do patients with negative PCR results have better virological outcomes than those with PVL (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 7, 2013 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news

Cocaine use can make otherwise resistant immune cells susceptible to HIV
In many ways, the spread of HIV has been fueled by substance abuse. Shared needles and drug users' high-risk sexual behaviors are just some of the ways that narcotics such as cocaine have played a key role in the AIDS epidemic in much of the world.   There is, however, relatively little research into how drugs can impact the body's defenses against the virus. But a new UCLA study published in the October issue of the Journal of Leukocyte Biology examines how cocaine affects a unique population of immune cells called quiescent CD4 T cells, which are resistant to the virus that causes AIDS.   The results: Coca...
Source: UCLA Newsroom: Health Sciences - October 2, 2013 Category: Universities & Medical Training Source Type: news

Single HIV Pill More Likely to Foster Adherence (CME/CE)
DENVER (MedPage Today) -- Veterans receiving highly active antiretroviral therapy (HAART) were more likely to adhere to treatment and less likely to be hospitalized when taking a single versus multiple tablets, researchers reported here. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - September 14, 2013 Category: Consumer Health News Source Type: news

HIV Patients Continue to Suffer From Severe Fatigue Despite HAART
In this study, HIV-infected patients experienced high levels of fatigue similar to those experienced by patients with chronic fatigue syndrome/myagalic encephalomyelitis. (Source: Consultant Live)
Source: Consultant Live - June 4, 2013 Category: Primary Care Source Type: news

HAART to heart for children with HIV
Long-term highly active antiretroviral therapy appears to protect children with HIV from associated cardiac problems, suggest study findings. (Source: MedWire News - Pediatrics)
Source: MedWire News - Pediatrics - April 23, 2013 Category: Pediatrics Source Type: news

HAART to heart for children with HIV
Long-term highly active antiretroviral therapy appears to protect children with HIV from associated cardiac problems, suggest study findings. (Source: MedWire News - Cardiology)
Source: MedWire News - Cardiology - April 23, 2013 Category: Cardiology Source Type: news

HAART to heart for children with HIV
Long-term highly active antiretroviral therapy appears to protect children with HIV from associated cardiac problems, suggest study findings. (Source: MedWire News - Pediatrics)
Source: MedWire News - Pediatrics - April 23, 2013 Category: Pediatrics Source Type: news

HAART to heart for children with HIV
Long-term highly active antiretroviral therapy appears to protect children with HIV from associated cardiac problems, suggest study findings. (Source: MedWire News - Infectious Diseases)
Source: MedWire News - Infectious Diseases - April 23, 2013 Category: Infectious Diseases Source Type: news

HAART Saves Heart in Kids with HIV (CME/CE)
(MedPage Today) -- Highly active antiretroviral therapy (HAART) appears to preserve cardiac function in children and adolescents infected with HIV, researchers found. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 22, 2013 Category: Cardiology Source Type: news

Highly Active Antiretroviral Therapies May Be Cardioprotective In HIV-Infected Children, Teens
Long-term use of highly active antiretroviral therapies (HAART) does not appear to be associated with impaired heart function in children and adolescents in a study that sought to determine the cardiac effects of prolonged exposure to HAART on children infected with the human immunodeficiency virus (HIV), according to a report published Online First by JAMA Pediatrics, a JAMA Network publication. Prior to contemporary antiretroviral therapies (ARTs), children infected with HIV were more likely to have heart failure. Steven E. Lipshultz, M.D., of the University of Miami Leonard M... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 22, 2013 Category: Consumer Health News Tags: HIV / AIDS Source Type: news

HIV-associated Fatigue in the Era of HAARTHIV-associated Fatigue in the Era of HAART
What may be driving HIV-associated fatigue in the HAART era? HIV Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 17, 2013 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news

HIV Drugs Ease Inflammation in 'Controllers' (CME/CE)
(MedPage Today) -- ATLANTA - Putting HIV controllers -- who ordinarily don't need therapy -- on highly active antiretroviral treatment (HAART) appeared to reduce markers of chronic inflammation, a researcher said here. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - March 4, 2013 Category: Consumer Health News Source Type: news

The 30-year fight against HIV
Since its identification as the cause of Aids in 1984, scientists have made major advancements in tackling virus1984 Retrovirus is discovered as cause of Aids and later named human immunodeficiency virus or HIV.1986 Clinical trials show that HIV patients taking AZT (azidothymidine), an antiretroviral drug initially developed as a cancer therapy, were living longer than those who did not. AZT is shown to manage, but not cure, HIV and reduce the rates of mother-to-child infection in pregnancy.1987 The US FDA approves AZT as the first antiretroviral to be used as a treatment for Aids.1995 Jeff Getty, Aids activist, becomes th...
Source: Guardian Unlimited Science - March 3, 2013 Category: Science Authors: Caroline Davies Tags: The Guardian News Health Medical research Aids and HIV Society Source Type: news

Kaposi’s sarcoma risk factors revealed
Scientists have uncovered an intriguing relationship between the risk for Kaposi’s sarcoma, smoking, and the use of highly active antiretroviral therapy. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - February 26, 2013 Category: Cancer & Oncology Source Type: news

Kaposi’s sarcoma risk factors revealed
Scientists have uncovered an intriguing relationship between the risk for Kaposi’s sarcoma, smoking, and the use of highly active antiretroviral therapy. (Source: MedWire News - Dermatology)
Source: MedWire News - Dermatology - February 25, 2013 Category: Dermatology Source Type: news

Kaposi’s sarcoma risk factors revealed
Scientists have uncovered an intriguing relationship between the risk for Kaposi’s sarcoma, smoking, and the use of highly active antiretroviral therapy. (Source: MedWire News - Infectious Diseases)
Source: MedWire News - Infectious Diseases - February 25, 2013 Category: Infectious Diseases Source Type: news

Ocular Complications of HIV/AIDS in the Era of HAARTOcular Complications of HIV/AIDS in the Era of HAART
What types of ocular diseases could potentially present in patients with HIV/AIDS on HAART? This new report explains. Expert Review of Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 14, 2013 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news